|
Chemical
Name:
Trifluoperazine hydrochloride Stelazine Brand
Name:
Stelazine Manufacturer:
SmithKline
Beecham Description:
A piperazine phenothiazine that probably blocks post
synaptic dopamine receptors in the brain. Indications
and Use: For
the manifestations of psychotic disorders.
Stelazine is effective for short-term treatment of generalized
non-psychotic anxiety; however, it is not to be used first-line because of
certain risks that alternative treatments do not have. Contraindications,
Warnings and Precautions:
Contraindicated
in patients in comatose states, central nervous system depression, blood
dyscrasias, bone marrow depression and pre-existing liver damage. The potentially fatal symptom complex of Neuroleptic
Malignant Syndrome (NMS) has been reported in association with this class of
drugs. Signs of NMS include muscle
rigidity, altered mental status, high fever, increased blood pressure, increased
heart rate and cardiac dysrhythmia. Tardive
Dyskinisia (TD) is a potentially irreversible, involuntary movement that may
develop. The highest prevalence of
TD is in the elderly, particularly women. Thrombocytopenia,
anemia, jaundice of the cholestatic type of hepatitis or liver damage have been
reported. The antiemetic effect of
Stelazine may mask the signs and symptoms. Adverse
Reactions:
Possible common side effects may include extrapyramidal reactions,
orthostatic hypotension, blurred vision, dry mouth, constipation, urinary
retention, and photosensitivity. Other side effects may include dizziness,
drowsiness, headache, insomnia, ECG changes, tachycardia, nausea, ocular changes
and weight gain. Dosing
Range:
Adjusted according to the needs of the person.
The usual starting dose for the psychotic adult is 2 to 5mg twice daily. |
|
These pages are solely for public informational purposes. The information cannot be relied on to make diagnoses or prescribe treatment in any individual. Persons who require such services should consult with a licensed professional. Send mail to ropa@redoakpsychiatry.com with questions or comments about this web site.© 2000 Red Oak Psychiatry Associates, P.A. Updated
11/26/2007
|